SHLA-I contaminating molecules as novel mechanism of ex vivo/in vitro transcriptional and posttranscriptional modulation of transforming growth factor-β1 in CD8+ T lymphocytes and neutrophils after intravenous immunoglobulin treatment

Transfusion

Volumn 50, Issue 3, 2010, Pages 547-555

  Ghio, Massimo ^a   Contini, Paola ^b   Negrini, Simone ^b   Proietti, Michele ^b   Gonella, Roberta ^b   Ubezio, Gianluca ^b   Ottonello, Luciano ^b   Indiveri, Francesco ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLOBIN; FAS LIGAND; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN; SOLUBLE FAS LIGAND; SOLUBLE HLA ANTIGEN CLASS 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ARTICLE; CD8+ T LYMPHOCYTE; COCULTURE; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOMODULATION; NEUTROPHIL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FAS LIGAND PROTEIN; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; LYMPHOCYTE ACTIVATION; MALE; NEUTROPHILS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77649195710     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02479.x     Document Type: Article

References (45)

1. Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 2006 46 : 741 53.
2. Imbach P, Barandun S, Baumgartner C, Hirt A, Hofer F, Wagner HP. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta 1981 36 : 81 6.
3. Kaveri SV, Lacroix-Desmazes S, Bayry J. The antiinflammatory IgG. NEJM 2008 359 : 307 9.
4. Seite JF, Shoenfelf Y, Youinou P, Hillion S. What is the contents of magic draft IVIg? Autoimmun Rev 2008 7 : 435 9.
5. Sewell WA, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology 2002 107 : 387 93.
6. Eibl MM. Intravenous immunoglobulins in neurological disorders: safety issues. Neurol Sci 2003 24 : S222 6.
7. Bayry J, Thirion M, Misra N, Thorenoor N, Delignat S, Lacroix-Desmazes S, Bellon B, Kaveri S, Kazatchkine MD. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol Sci 2003 24 : S217 21.
8. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. NEJM 2001 345 : 747 55.
9. Mouzaki A, Theodoropoulos M, Gianakopoulos I, Vlaha V, Kyrtsonosis MC, Maniatis A. Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenia purpura (ITP) at presentation and their modulation by intravenous immunoglobulin (IVIg) treatment: thei role in prognosis. Blood 2002 100 : 1774 9.
10. Satcher D. Testimony on immune globulin shortage. 1998. Washington, DC : U.S. Department of Health and Human Services. [cited 2009 Oct 8] Available from: http://www.hhs.gov/asl/testify/t980507b.html
11. van Mirre E, Teeling JL, van der Meer JW, Bleeker WK, Hack CE. Monomeric IgG in intravenous Ig preparation is a functional antagonist of FcγRII and FcγRIIIb. J Immunol 2004 173 : 332 9.
12. Wassmuth R, Hauser IA, Schuler K, Erxleben H, Arnold ML, Koelman CA, Claas FH, Kalden JR. Differential inhibitory effects of intravenous immunoglobulin preparations on HLA-alloantibodies in vitro. Transplantation 2001 71 : 1436 42.
13. Blasczyk R, Westhoff U, Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993 341 : 789 90.
14. Grosse-Wilde H, Blasczyk R, Westhoff U. Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations. Tissue Antigens 1992 39 : 74 7.
15. Prasad A, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, Kaveri SV. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998 161 : 3781 90.
16. Ghio M, Ottonello L, Contini P, Amelotti M, Mazzei C, Indiveri F, Puppo F, Dallegri F. Transforming growth factor-beta1 in supernatants from stored red blood cells inhibits neutrophil locomotion. Blood 2003 102 : 1100 7.
17. Kekow J, Reinhold D, Pap T, Ansorge S. Intravenous immunoglobulins and transforming growth factor β. Lancet 1998 351 : 184 5.
18. Pap T, Reinhold D, Kekow J. Effects of intravenous immunoglobulins on disease activity and cytokine plasma levels in rheumatoid arthritis. Scand J Rheumatol 1998 27 : 157 9.
19. 2 after treatment with intravenous immunoglobulins in childhood autoimmune diseases. Pediatr Allergy Immunol 2009 20 : 261 5.
20. Ghio M, Contini P, Puppo F, Indiveri F. The immunomodulatory effect of blood transfusions and intravenous immunoglobulins: the role of the soluble molecules of the Class-I-major histocompatibility complex and Fas ligand. Ann Ital Med Int 2000 15 : 70 4.
21. Tanabe M, Sekimata M, Ferrone S, Takiguchi M. Structural and functional analysis of monomorphic determinants recognized by monoclonal antibodies reacting with the HLA class I alpha 3 domain. J Immunol 1992 148 : 3202 9.
22. Pellegrino MA, Ng AK, Russo C, Ferrone S. Heterogeneous distribution of the determinants defined by monoclonal antibodies on HLA-A and B antigens bearing molecules. Transplantation 1982 34 : 18 23.
23. Hoffman RA, Kung PC, Hansen WP, Goldstein G. Simple and rapid measurement of human T lymphocytes and their subclasses in peripheral blood. Proc Nat Acad Sci U S A 1980 77 : 4914 7.
24. Giacobini P, Imberbi L, Aguzzib A, Fisher PB, Trinchieri G, Ferrone S. Immunochemical analysis of the modulation of human melanoma associated antigens by DNA recombinant immune interferon. J Immunol 1985 135 : 2887 94.
25. Puppo F, Contini P, Ghio M, Brenci S, Scudeletti M, Filaci G, Ferronel S, Indiveri F. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes. Int Immunol 2000 12 : 195 203.
26. Ottonello L, Ghio M, Contini P, Bertolotto M, Bianchi G, Montecucco F, Colonna M, Mazzei C, Dallegri F, Indiveri F. Nonleukoreduced red blood cell transfusion induces a sustained inhibition of neutrophil chemotaxis by stimulating in vivo production of transforming growth factor-beta1 by neutrophils: role of the immunoglobulinlike transcript 1, sFasL, and sHLA-I. Transfusion 2007 47 : 1395 404.
27. Contini P, Ghio M, Merlo A, Poggi A, Indiveri F, Puppo F. Apoptosis of antigen-specific T lymphocytes upon the engagement of CD8 by soluble HLA class I molecules is Fas ligand/Fas mediated: evidence for the involvement of p56lck, calcium calmodulin kinase II, and calcium-independent protein kinase C signaling pathways and for NF-kappaB and NF-AT nuclear translocation. J Immunol 2005 175 : 7244 54.
28. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cavé H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, González M, Viehmann S, Malec M, Saglio G, van Dongen JJ. Standardization and quality control studies of "real-time" quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003 17 : 2318 57.
29. Ciotti P, Garuti A, Ballestrero A, Cirmena G, Chiaramondia M, Baccini P, Bellone E, Mandich P. Reliability and reproducibility of a RNA preamplification method for low-density array analysis from formalin-fixed paraffin-embedded breast cancer samples. Diagn Mol Pathol 2009 18 : 112 8.
30. Vassilev T, Mihaylova N, Voynova E, Nikolova M, Kazatchkine M, Kaveri S. IgM-enriched human intravenous immunoglobulin suppresses T lymphocyte functions in vitro and delays the activation of T lymphocytes in hu-SCID mice. Clin Exp Immunol 2006 145 : 108 15.
31. Prasad NK, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, Kaveri SV. Therapeutic preparation of normal polyspecific IgG (IVIg) induces apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving Fas apoptotic pathway. J Immunol 1998 161 : 3781 90.
32. Hartung P. Advances in the understanding of the mechanism of action of IVIg. J Neurol 2008 255 : 3 6.
33. Gürcan HM, Ahmed AR. Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders. Ann Pharmacother 2007 41 : 812 23.
34. Toubi E, Kessel A, Shoenfeld Y. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol 2005 66 : 395 402.
35. Dalakas MC. The role of high-dose immune globulin intravenous in the treatment of dermatomyositis. Int Immunopharmacol 2006 6 : 550 6.
36. Ghio M, Contini P, Mazzei C, Brenci S, Barberis G, Filaci G, Indiveri F, Puppo F. Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood 1999 3 : 1770 7.
37. Ghio M, Contini P, Ubezio G, Mazzei C, Puppo F, Indiveri F. Immunomodulatory effects of blood transfusions: the synergic role of soluble HLA Class I free heavy-chain molecules detectable in blood components. Transfusion 2008 48 : 1591 7.
38. Ghio M, Contini P, Mazzei C, Merlo A, Filaci G, Setti M, Indiveri F, Puppo F. In vitro immunosuppressive activity of soluble HLA class I and Fas ligand molecules: do they play a role in autologous blood transfusion? Transfusion 2001 41 : 988 96.
39. Spaggiari GM, Contini P, Pondero A, Carosio R, Puppo F, Indiveri F, Zocchi MR, Poggi A. Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction. Blood 2002 100 : 4098 107.
40. Li MO, Flavell RA. TGF-beta: a master of all T cell trades. Cell 2008 134 : 392 404.
41. Wahl SM. Transforming growth factor-beta: innately bipolar. Curr Opin Immunol 2007 19 : 55 62.
42. Wang H, Xu J, Ji X, Yang X, Sun K, Liu X, Shen Y. The abnormal apoptosis of T cell subsets and possible involvement of IL-10 in systemic lupus erythematosus. Cell Immunol 2005 235 : 117 21.
43. Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008 29 : 608 15.
44. Bayry J, Karatchkine MD, Kaveri SV. Shortage of human intravenous immunoglobulin-reasons and possible solutions. Nat Clin Pract 2007 3 : 120 1.
45. Kaveri S, Vassilev T, Hurez V, Lengagne R, Lefranc C, Cot S, Pouletty P, Glotz D, Kazatchkine MD. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996 97 : 856 69.